Hybridoma-derived neutralizing monoclonal antibodies against Beta and Delta variants of SARS-CoV-2 in vivoArticle Published on 2023-04-012023-07-11 Journal: Virologica Sinica [Category] COVID19(2023년), [키워드] B.1.351 B.1.617.2 COVID-19 monoclonal antibody SARS-CoV-2. [DOI] 10.1016/j.virs.2022.12.007 PMC 바로가기
The efficacy and effectiveness of the COVID-19 vaccines in reducing infection, severity, hospitalization, and mortality: a systematic review감염, 중증도, 입원 및 사망률 감소에 대한 COVID-19 백신의 효능 및 효과: 체계적인 검토Article Published on 2022-12-312022-09-11 Journal: Human vaccines & immunotherapeutics [Category] COVID19(2023년), SARS, 변종, [키워드] accelerated approved B.1.1.7 B.1.351 B.1.351 variants COVID-19 COVID-19 pandemic COVID-19 vaccine COVID-19 vaccines database disease transmission effective Effectiveness Efficacy effort growth Hospitalization identify inclusion criteria Infection infections Mortality Pfizer Pfizer/BioNTech populations reduced reducing regimen required Seven severity systematic literature search systematic review Vaccine Vaccine development vaccine. Vaccines variants was performed [DOI] 10.1080/21645515.2022.2027160 PMC 바로가기 [Article Type] Article
COVID vaccine efficacy against the B.1.351 (“South African”) variant-The urgent need to lay the groundwork for possible future challenge studiesB.1.351("남아프리카") 변종에 대한 코로나바이러스 백신 효능-가능한 미래의 도전 연구를 위한 토대를 마련하는 시급한 필요성Article Published on 2022-12-312022-09-11 Journal: Human vaccines & immunotherapeutics [Category] COVID19(2023년), SARS, 변종, [키워드] B.1.351 COVID Efficacy Vaccine [DOI] 10.1080/21645515.2021.1917240 PMC 바로가기 [Article Type] Article
Neutralizing antibodies to SARS-CoV-2 variants of concern including Delta and Omicron in subjects receiving mRNA-1273, BNT162b2, and Ad26.COV2.S vaccinesArticle Published on 2022-12-012022-11-15 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] Ad26.COV2.S Ad26.COV2.S vaccine antibody B.1.1.529 B.1.1.7 B.1.351 B.1.617.2 Beta BNT162b2 BNT162b2 vaccine booster center contributed Control COVID-19 Delta dose Effectiveness elicited faster FIVE Gamma immunization moderate mRNA-1273 mRNA-based vaccine Mutation Neutralizing Neutralizing antibodies neutralizing antibody omicron P.1 postvaccination prevention Protein pseudovirus receiving recipient recommendation robust SARS-CoV-2 SARS-CoV-2 vaccine SARS-CoV-2 variant subject Support vaccination Vaccine vaccine efficacy variants of concern variants of concern (VOCs). VoC VOCs wild type [DOI] 10.1002/jmv.28032 PMC 바로가기
Binding and neutralizing abilities of antibodies towards SARS-CoV-2 S2 domainSARS-CoV-2 S2 도메인에 대한 항체의 결합 및 중화 능력Article Published on 2022-11-302022-09-11 Journal: Human vaccines & immunotherapeutics [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 antibodies antibody B.1.1.7 B.1.351 B.1.617.2 B.1.621 binding binding activity carried conserved convalescent patient coronavirus coronavirus 2 coronavirus disease Coronavirus disease 2019 COVID-19 determined by domain ELISA enzyme enzyme-linked immunosorbent enzyme-linked immunosorbent assay evaluated Evidence Immune escape immune protection mAb mAbs MERS MERS-CoV Middle East Middle East respiratory syndrome Middle East respiratory syndrome Coronavirus molecular monoclonal antibodies monoclonal antibody N Terminal N terminal domain NAbs Neutralization assay neutralization assay. Neutralizing Neutralizing activity Neutralizing antibodies neutralizing antibody NTD P.1 Protein pseudo-virus RBD Receptor binding domain reported Research respiratory Result S protein S proteins S2 protein S2 subunit SARS-CoV SARS-CoV-2 SARS-CoV-2 RBD SARS-CoV-2 S SARS-CoV-2 S2 SARS-CoV-2 WT Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus significantly specific antibodies subunit target targets terminal Vaccine design variant variants wild-type [DOI] 10.1080/21645515.2022.2055373 PMC 바로가기 [Article Type] Article
Whole-genome sequence analysis reveals the circulation of multiple SARS-CoV-2 variants of concern in Nairobi and neighboring counties, Kenya between March and July 2021Article Published on 2022-11-082022-11-16 Journal: Virology Journal [Category] SARS, 변종, [키워드] adaptive analysis analyzed B.1.1.7 B.1.351 B.1.617.2 Beta bioinformatics circulation community transmission comparison Coronaviruses COVID-19 COVID-19 cases Delta Epidemics genome sequence increase in Kenya Lineage majority Mutation Neutralizing antibodies Oxford Nanopore Technologies Phylogenetic Prevalence protocol reduced Region regions reveal RNA RT-PCR SAR-CoV-2 SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 strain SARS-CoV-2 variant SARS-CoV-2. sequence Sequence analysis Sequencing Spread Strains study period the SARS-CoV-2 variant virulence virus virus transmissibility VoC was performed [DOI] 10.1186/s12985-022-01895-y PMC 바로가기
Updated vaccine protects against SARS-CoV-2 variants including Omicron (B.1.1.529) and prevents transmission in hamstersArticle Published on 2022-11-042022-11-15 Journal: Nature Communications [Category] SARS, 변종, 진단, 치료기술, [키워드] Antigen B.1.1.529 B.1.1.7 B.1.351 B.1.617.2 Beta block Community COVID-19 vaccine current Delta delta variant detectable Efficacy eliminating expressed Fever Gamma hamster immunization Lineage Lung pathology maintain Neutralizing antibody response omicron P.1 pandemic predominant Prevent PROTECT SARS-CoV-2 strains SARS-CoV-2 variant sequence Spread titre Transmission Vaccine variants variants of concern vectored vaccine virus VoC VOCs [DOI] 10.1038/s41467-022-34439-7 PMC 바로가기
Naturally occurring spike mutations influence the infectivity and immunogenicity of SARS-CoV-2Article Published on 2022-11-012022-11-15 Journal: Cellular and Molecular Immunology [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] A570D A701V addition Affect affected antibodies antigenicity B.1.1.529 B.1.1.7 B.1.1.7 lineage B.1.351 B.1.617.2 BALB/c mice binding circulating cross-neutralization activity D1118H decrease Del Delta determine DNA vaccine Effects Efficiency elicited humoral immune response immune evasion immunized immunogen in vitro investigated K417N L18F Lineage Mutation NAbs Naturally neutralization Neutralizing Neutralizing antibodies neutralizing antibody NTD omicron opposite overcome P681H Pseudotyped viruses reduced S982A SARS-CoV-2 SARS-CoV-2 variant sera significantly increased single mutation single mutations spike mutation T cell T cell responses T-cell Response T716I tested the RBD Transmissibility unlikely Vaccine vaccine immunogenicity vaccine immunogenicity. variants of concern viral entry viral infectivity VoC VOCs was determined weakened [DOI] 10.1038/s41423-022-00924-8 PMC 바로가기
Genomic Epidemiology and Serology Associated with a SARS-CoV-2 R.1 Variant Outbreak in New JerseyArticle Published on 2022-10-262022-11-15 Journal: mBio [Category] COVID19(2023년), SARS, 변종, 유전자 메커니즘, 진단, 치료기술, [키워드] acute respiratory syndrome antibody antibody resistance attack rate B.1.351 B.1.526 Care caused characteristic Clinical use collected Community Complete coronavirus COVID-19 Critical E484K mutation Evidence Examining exhibit exhibited hcp Health highlight individual infected individuals Infection Inpatient Lineage loss of activity monoclonal antibody Mutation N-terminal domain neutralization capacity Neutralizing antibody response neutralizing capacity New nosocomial NTD outbreak P.1 Patient plasma positive professional professionals proportion pseudovirus psychiatric facility Receptor binding domain reported reverse transcription robust SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 variant sera Spike protein Symptom symptomatic COVID-19 disease tested the SARS-CoV-2 the United State treat vaccinated individual vaccinated individuals vaccination Vaccine variant variants of concern variants of concern. VOCs wild type [DOI] 10.1128/mbio.02141-22 PMC 바로가기
B.1.351 SARS-CoV-2 Variant Exhibits Higher Virulence but Less Viral Shedding than That of the Ancestral Strain in Young Nonhuman PrimatesArticle Published on 2022-10-262022-11-16 Journal: Microbiology Spectrum [Category] COVID19(2023년), SARS, 변종, 유전자 메커니즘, [키워드] addition Alpha animal model association B.1.351 Beta caused changes in Characteristics Chinese circulating Clinical signs contribute determine distribution drugs early stage Efficacy and safety elevated exhibited IFN-γ IL-17 Infection Inflammatory Inflammatory cytokine interferon gamma interleukin 17 investigated less Lower respiratory tract lung tissue mechanisms mutated Necrosis NHP NHPs nonhuman primate pathogenesis of SARS-CoV-2 pathogenic pathogenicity pathological changes primate provide pulmonary inflammation reduced replicated Research rhesus macaque SARS-CoV-2 SARS-CoV-2 strain SARS-CoV-2 vaccine SARS-CoV-2 variant SARS-CoV-2 variants severe lung injury shedding spike-specific T-cell response strain Strains tissue TNF-α Transmission upper respiratory tract Vaccine variant variants of concern viral distribution viral shedding virulence virulence. virulent VoC VOCs were infected [DOI] 10.1128/spectrum.02263-22 PMC 바로가기